Pancreatic cancer
Substantial progress has been made in our understanding of the biology of pancreatic
cancer, and advances in patients' management have also taken place. Evidence is …
cancer, and advances in patients' management have also taken place. Evidence is …
Pancreatic cancer
M Hidalgo - New England journal of medicine, 2010 - Mass Medical Soc
Deaths from pancreatic ductal adenocarcinoma, also known as pancreatic cancer, rank
fourth among cancer-related deaths in the United States, yet the causes of pancreatic cancer …
fourth among cancer-related deaths in the United States, yet the causes of pancreatic cancer …
Pancreatic adenocarcinoma, version 2.2017, NCCN clinical practice guidelines in oncology
MA Tempero, MP Malafa, M Al-Hawary… - Journal of the National …, 2017 - jnccn.org
Ductal adenocarcinoma and its variants account for most pancreatic malignancies. High-
quality multiphase imaging can help to preoperatively distinguish between patients eligible …
quality multiphase imaging can help to preoperatively distinguish between patients eligible …
Effect of chemoradiotherapy vs chemotherapy on survival in patients with locally advanced pancreatic cancer controlled after 4 months of gemcitabine with or without …
Importance In locally advanced pancreatic cancer, the role of chemoradiotherapy is
controversial and the efficacy of erlotinib is unknown. Objectives To assess whether …
controversial and the efficacy of erlotinib is unknown. Objectives To assess whether …
Recent progress in pancreatic cancer
Answer questions and earn CME/CNE Pancreatic cancer is currently one of the deadliest of
the solid malignancies. However, surgery to resect neoplasms of the pancreas is safer and …
the solid malignancies. However, surgery to resect neoplasms of the pancreas is safer and …
[HTML][HTML] Factors predicting response, perioperative outcomes, and survival following total neoadjuvant therapy for borderline/locally advanced pancreatic cancer
Objective: To identify predictive factors associated with operative morbidity, mortality, and
survival outcomes in patients with borderline resectable (BR) or locally advanced (LA) …
survival outcomes in patients with borderline resectable (BR) or locally advanced (LA) …
Gemcitabine alone versus gemcitabine plus radiotherapy in patients with locally advanced pancreatic cancer: an Eastern Cooperative Oncology Group trial
PJ Loehrer Sr, Y Feng, H Cardenes… - Journal of Clinical …, 2011 - ascopubs.org
Purpose The purpose of this trial was to evaluate the role of radiation therapy with
concurrent gemcitabine (GEM) compared with GEM alone in patients with localized …
concurrent gemcitabine (GEM) compared with GEM alone in patients with localized …
Advanced pancreatic carcinoma: current treatment and future challenges
A Stathis, MJ Moore - Nature reviews Clinical oncology, 2010 - nature.com
Pancreatic adenocarcinoma is the most lethal of the solid tumors and the fourth leading
cause of cancer-related death in North America. Most patients present with locally advanced …
cause of cancer-related death in North America. Most patients present with locally advanced …
Pancreatic cancer: yesterday, today and tomorrow
D Ansari, B Tingstedt, B Andersson, F Holmquist… - Future …, 2016 - Taylor & Francis
Pancreatic cancer is one of our most lethal malignancies. Despite substantial improvements
in the survival rates for other major cancer forms, pancreatic cancer survival rates have …
in the survival rates for other major cancer forms, pancreatic cancer survival rates have …
Phase 2 multi‐institutional trial evaluating gemcitabine and stereotactic body radiotherapy for patients with locally advanced unresectable pancreatic adenocarcinoma
BACKGROUND This phase 2 multi‐institutional study was designed to determine whether
gemcitabine (GEM) with fractionated stereotactic body radiotherapy (SBRT) results in …
gemcitabine (GEM) with fractionated stereotactic body radiotherapy (SBRT) results in …